ArticleInvestigative ophthalmology & visual science2011
Can clinical signs of trachoma be used after multiple rounds of mass antibiotic treatment to indicate infection?
Article in Investigative ophthalmology & visual science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.Ophthalmic epidemiology · 2019Trial
- Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger.PLoS neglected tropical diseases · 2019Trial
- Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.JAMA ophthalmology · 2013Trial
- A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.PLoS neglected tropical diseases · 2013Trial
- Comparison of Methods for Assessing Chlamydia trachomatis Transmission Intensity: A Systematic Review.The American journal of tropical medicine and hygiene · 2026Article
- Azithromycin Reduction to Reach Elimination of Trachoma (ARRET): study protocol for a cluster randomized trial of stopping mass azithromycin distribution for trachoma.BMC ophthalmology · 2021Article
- The burden of and risk factors for active trachoma in the North and South Wollo Zones of Amhara Region, Ethiopia: a cross-sectional study.Infectious diseases of poverty · 2017Article
- Measuring Trachomatous Inflammation-Intense (TI) When Prevalence Is Low Provides Data on Infection With Chlamydia trachomatis.Investigative ophthalmology & visual science · 2017Article
- The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment.PLoS neglected tropical diseases · 2016Review
- Social Sciences for the Prevention of Blindness.Tropical medicine and health · 2015Review
- Serology for trachoma surveillance after cessation of mass drug administration.PLoS neglected tropical diseases · 2015Article
- Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration.BMC infectious diseases · 2014Article
- The limits of medical interventions for the elimination of preventable blindness.Tropical medicine and health · 2014Article
- Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.PLoS neglected tropical diseases · 2014Article
- Field evaluation of the Cepheid GeneXpert Chlamydia trachomatis assay for detection of infection in a trachoma endemic community in Tanzania.PLoS neglected tropical diseases · 2013Article
- Will the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutions.TheScientificWorldJournal · 2013Review
- Trachoma: an update on prevention, diagnosis, and treatment.Current opinion in ophthalmology · 2012Review
- CT694 and pgp3 as serological tools for monitoring trachoma programs.PLoS neglected tropical diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo evaluate combinations of clinical signs, using a modified World Health Organization (WHO) grading scheme, to predict a very low prevalence of infection at the community level after at least three rounds of mass drug administration (MDA).
methodsSeventy-one villages had three to seven rounds of MDA. A random sample of 7828 children ages 5 years and younger was evaluated for trachoma, and determination of Chlamydia trachomatis infection was made. Proportions of children positive for infection were evaluated against all possible combinations of follicular trachoma (TF) and inflammatory trachoma (TI). High-risk signs (HRS) for infection were defined as those indicating the infection prevalence was >20%. The sensitivity and specificity of prevalence of HRS in identifying communities with infection was examined.
resultsThe median community infection prevalence was 3.8% interquartile range (IQR) (1.8%, 7.7%); the median trachoma prevalence was 9.4%, IQR (6.6%, 15%). Severe TI, combination of TF and TI (WHO criteria), or severe TF with signs of inflammation were predictive of infection in the community, but the absence of these HRS was not an indicator of low infection rates.
conclusionsThe use of HRS to determine the infection status of a community was not useful in predicting whether MDA could be stopped.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.